Siegfried and BioNTech Sign Contract for the Aseptic Fill & Finish of a COVID-19 Vaccine

September 14, 2020

The Siegfried Group (SIX: SFZN) announces that it has signed a cooperation and supply agreement with Biopharmaceutical New Technologies (BioNTech), a German immunotherapy company, for the large-scale filling and packaging of commercial quantities of BNT162b2, an innovative COVID-19 vaccine candidate. Following successful approval, the vaccine developed by BioNTech in cooperation with Pfizer, a US American pharmaceutical company, will be filled by Siegfried at its Hameln site from mid 2021 onwards.

Siegfried CEO Dr. Wolfgang Wienand: “We are proud to make an important contribution toward combatting the pandemic through this partnership, and we are determined to support BioNTech in the best possible way. As a leading CDMO company with a strong global manufacturing network, Siegfried is in a position to take on technologically demanding tasks at short notice and to quickly build up the necessary capacities.”

The BNT162b2 vaccination, jointly developed by BioNTech and Pfizer, is currently undergoing global pivotal clinical phase 2/3 trials. If the study is successful, it is planned to seek regulatory review in October 2020. For the aseptic filling and packaging ("fill & finish") of the vaccine, Siegfried will invest in a dedicated production line at its Hameln (Germany) site and provide special storage capacity. The first phase of the agreement will end 2022, with the shared intention to expand the cooperation into a strategic partnership between BioNTech and Siegfried.

Marianne Späne, Global Head Business Development & Sales at Siegfried: "We very much look forward toward the cooperation with this pioneer company for biopharmaceuticals. This contract, for which we will make full use of our technical capabilities and high quality standards, represents the first step for us toward a long-term partnership with further potential.”

placeholder

Peter A. Gehler
Chief Communication
Officer
Untere Bruehlstrasse 4
4800 Zofingen
Switzerland

Phone +41 62 746 1148
peter.gehler@siegfried.ch

placeholder

Siegfried AG
Reto Suter
CFO
Untere Bruehlstrasse 4
4800 Zofingen
Switzerland

Phone +41 62 746 11 35
reto.suter@siegfried.ch

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain (from 1.1.2021), France, Malta, the USA and China. In 2020, the company achieved sales of 845.1 million Swiss francs and employed on 31.12.2020 about 2'500 people at nine sites on three continents. Following the acquisition of two sites in Spain as per 01.01.2021, this number rose to approximately 3'500 employees. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services. 

Cautionary Statements Regarding Forward-Looking Statements 

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.